Skip to main content

Real-World Predictors of Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients with Chronic Coronary Artery Disease and/or Peripheral Arterial Disease

A Correction to this article was published on 13 January 2020

This article has been updated

Abstract

Introduction

Collectively, coronary artery disease (CAD) and peripheral artery disease (PAD) are highly prevalent and are associated with increased risk of major adverse cardiovascular events (MACE) and major adverse limb events (MALE). Improved ability to identify those at highest risk of these events may help optimize secondary prevention efforts in this population.

Methods

Using the Optum Integrated Database, a healthcare claims database linked to electronic medical records (EMR), we identified patients with CAD and/or PAD between January 1, 2009, and September 30, 2016. Index date was the earliest date on which chronic and stable disease was established. Follow-up ran from index date until earliest of patient death, plan disenrollment, or end of study. We developed multivariate Cox proportional hazards models to identify predictors of MACE and/or MALE, limited to measures presumed available to clinicians during patient encounters (e.g., age, presence of selected comorbidities).

Results

A total of 20,932 patients met all selection criteria; 86.9% had CAD and 26.1% had PAD; 13% (n = 2753) experienced MACE and/or MALE during a mean follow-up of 2.3 years, for a rate of 7.1 events per 100 person-years (PYs). We identified 11 predictors of MACE and/or MALE. Most (95.1%) patients had ≥ 1 predictors; 34.0% and 6.9% had ≥ 4 and ≥ 6, respectively. Incidence of MACE and/or MALE was strongly correlated with number of predictors (r2 = 0.98), ranging from 2.3 per 100 PYs among those without predictors (4.9% of patients) to 18.7 per 100 PYs among those with ≥ 6 (6.9%). Patients with ≥ 1 predictor experienced 7.4 MACE and/or MALE per 100 PYs.

Conclusion

Readily identifiable predictors can be used to identify subgroups with chronic CAD and/or PAD at elevated risk of MACE and/or MALE. Further research is required to understand the degree to which these subgroups may benefit from early identification and treatment with secondary prevention therapies.

Funding

Janssen Pharmaceuticals.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

Change history

  • 13 January 2020

    In the original article. The third author name is incorrect. The correct name is Nicholas J. Leeper.

References

  1. 1.

    Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016;4(13):256.

    PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603.

    PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med. 2009;25(4):563–77 (vii).

    PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350–7.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(12):e726–79.

    PubMed  Google Scholar 

  6. 6.

    World Health Organization (WHO). The top 10 causes of death. 2018. http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.Published.201/. Accessed 30 Nov 2018.

  7. 7.

    Khoury H, Lavoie L, Welner S, Folkerts K. The burden of major adverse cardiac events and antiplatelet prevention in patients with coronary or peripheral arterial disease. Cardiovasc Ther. 2016;34(2):115–24.

    PubMed  Article  Google Scholar 

  8. 8.

    Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835–42.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation. 2000;101(22):2557–67.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345–53.

    PubMed  Article  Google Scholar 

  11. 11.

    Paramore LC, Thomas SK, Knopf KB, Cragin LS, Fraeman KH. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6(1):52–8.

    PubMed  Article  Google Scholar 

  12. 12.

    Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation. 1998;98(18):1860–8.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation. 1995;91(6):1659–68.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Janssen US. FDA approves XARELTO® (rivaroxaban) to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD). 2018. https://www.janssen.com/us-fda-approves-xareltor-rivaroxaban-reduce-risk-major-cardiovascular-events-patients-chronic. Updated October 11. Accessed 30 Nov 2018.

  15. 15.

    Eikelboom J, Connolly S, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–30.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2011;183(7):E411–9.

    PubMed  PubMed Central  Google Scholar 

  17. 17.

    Mitchell SL. Care of patients with advanced dementia. 2018. https://www.uptodate.com/contents/care-of-patients-with-advanced-dementia#H423254540. Accessed 18 Sep 2019.

  18. 18.

    Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J Med. 2009;361(16):1529–38.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Luepker RV, Steffen LM, Duval S, Zantek ND, Zhou X, Hirsch AT. Population trends in aspirin use for cardiovascular disease prevention 1980–2009: the Minnesota Heart Survey. J Am Heart Assoc. 2015;4:12.

    Article  Google Scholar 

  20. 20.

    Ferencik M, Mayrhofer T, Bittner DO, et al. Use of high-risk coronary atherosclerotic plaque detection for risk stratification of patients with stable chest pain: a secondary analysis of the PROMISE randomized clinical trial. JAMA Cardiol. 2018;3(2):144–52.

    PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Kronzon I, Tunick PA. Aortic atherosclerotic disease and stroke. Circulation. 2006;114(1):63–75.

    PubMed  Article  Google Scholar 

Download references

Acknowledgements

Funding

This work was sponsored by Janssen Pharmaceuticals who were responsible for financing the study and the decision to publish the findings. The journal’s Rapid Service Fee was funded by Janssen Pharmaceuticals.

Editorial Assistance

We thank Sean Smith of Evidera for his editorial assistance in the development of this manuscript. This assistance was funded by Janssen Pharmaceuticals.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

Ariel Berger is employed by Evidera, a research and consulting company to the biopharma industry. In this salaried position, he works with a variety of companies and organizations and is precluded from receiving payment or honoraria directly from these organizations for services rendered. Brian Murphy is employed by Evidera, a research and consulting company to the biopharma industry. In this salaried position, he works with a variety of companies and organizations and is precluded from receiving payment or honoraria directly from these organizations for services rendered. Beth Nordstrom is employed by Evidera, a research and consulting company to the biopharma industry. In this salaried position, she works with a variety of companies and organizations and is precluded from receiving payment or honoraria directly from these organizations for services rendered. Nicholas J. Leeper reports other modest research support from Bayer and Janssen. Windsor Ting reports a modest research grant from Janssen. Jeffrey Berger reports other modest research support from Janssen and AstraZeneca. Qi Zhao is currently employed at Eisai, Woodcliff Lake, NJ, USA. Alex Simpson was an employee of Evidera at the time research was conducted.

Compliance with Ethics Guidelines

This was a retrospective database study that used only completely de-identified data. Accordingly, institutional review board approval and informed consent were neither required nor sought.

Data Availability

The datasets generated during and/or analyzed during the current study are not publicly available because of being “work for hire,” but are available from the corresponding author on reasonable request.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ariel Berger.

Additional information

The original version of this article was revised due to incorrect name of the third author in the author group.

Enhanced Digital Features

To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.9963986.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Berger, A., Simpson, A., Leeper, N.J. et al. Real-World Predictors of Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients with Chronic Coronary Artery Disease and/or Peripheral Arterial Disease. Adv Ther 37, 240–252 (2020). https://doi.org/10.1007/s12325-019-01132-z

Download citation

Keywords

  • Coronary artery disease
  • Incidence
  • Major adverse cardiovascular events (MACE)
  • Major adverse limb events (MALE)
  • Peripheral arterial disease
  • Predictors